Marketing: Page 49
-
Shire files injunction against Roche hemophilia competitor
Shire claims potential hemophilia rival Roche inaccurately characterized its experimental drug's safety profile and unlawfully disparaged Shire's existing treatment.
By Suzanne Elvidge • July 10, 2017 -
Report: NFL losing top ad spenders as Viagra, Cialis drop out
Pfizer's Viagra reportedly bought $31 million in pro football inventory last year.
By David Kirkpatrick , Peter Adams • July 10, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Generic drug association sues to stop state price-gouging law
The Association for Accessible Medicines labeled Maryland's newly passed drug pricing law an "unconstitutional overreach," filing suit to block it from taking effect.
By Ned Pagliarulo • July 7, 2017 -
Biotech IPOs more than double in Q2
The U.S. IPO market hit a two-year high in the second quarter, with 14 healthcare companies making the private-to-public switch, according to Renaissance Capital.
By Jacob Bell • July 7, 2017 -
Endo caves to FDA pressure, removes Opana from market
The drugmaker acquiesces to agency requests to remove its opioid pain medication from the market in light of the ongoing abuse epidemic.
By Lisa LaMotta • July 6, 2017 -
Amid industry-wide pricing backlash, Vertex raises Orkambi cost
The cystic fibrosis-focused drugmaker upped the list price for Orkambi by 5%.
By Jacob Bell • July 5, 2017 -
Industry paid $8.2B to docs, hospitals last year
Roche, Novartis and Pfizer each spent more than $475 million in total 2016 payments, with fellow multinational drugmakers not far behind.
By Ned Pagliarulo • July 5, 2017 -
Kaléo launches counterclaims against Express Scripts
The PBM broke contractual obligations and owes the drugmaker more than $5 million, according to the recently filed claims.
By Jacob Bell • July 5, 2017 -
Deep Dive
A head above the rest? Drugmakers face off in migraine market
CGRP inhibitors could represent a step-change in the treatment of migraine — and potentially rake in billions of dollars in future sales for the four drugmakers developing them.
By Ned Pagliarulo • June 30, 2017 -
FDA's first steps in drug competition plan: get more generics approved
The agency rolled out a new list highlighting branded medicines that lack generic competition and updated protocols so copycat drugs can move to market faster.
By Jacob Bell • June 28, 2017 -
Clarus resubmits oral hormone therapy to FDA
The small biotech again filed its testosterone replacement drug for approval, with the hope that new data will clear a path to market.
By Jacob Bell • June 27, 2017 -
CHMP decisions: Novartis locks up backing for Kisqali
A key committee of the EU regulator also recommended approval for a liver cancer drug from Aveo Oncology.
By Ned Pagliarulo • June 23, 2017 -
Novartis anti-inflammatory drug locks down landmark results in CV study
A six-year Phase 3 study showed Ilaris reduced the risk of cardiovascular events, a surprise result which buoys the Swiss pharma's heart drug portfolio.
By Jacob Bell • June 22, 2017 -
Courtesy of Eli Lilly
#BIO2017 Day 3 roundup: Building value and what it costs
There was a lot going on Wednesday at the BIO International Convention, as well as in and around the San Diego area — a major biotech hub.
By Lisa LaMotta • June 21, 2017 -
Can too many safety warnings overwhelm consumers?
Two FDA experiments will test whether repetition of safety warnings in DTC ads negatively affects consumers’ attention to drug risks.
By Barbara Boughton • June 21, 2017 -
Shire's ADHD drug secures FDA OK
The Irish pharma expects to start commercializing Mydayis in the third quarter.
By Jacob Bell • June 21, 2017 -
Deep Dive
FDA targets regulatory 'gaming' to boost generic competition
While the FDA has no direct role in drug pricing, agency head Scott Gottlieb hopes his planned actions could help address rising costs — at least in part.
By Ned Pagliarulo • June 21, 2017 -
Pricing pressures lower drug sales forecasts, new report finds
It was the first lowering of long-term sales expectations in the 10-year history of EvaluatePharma's World Preview reports.
By Jacob Bell • June 21, 2017 -
Humira shows its staying power
Pfizer had hoped head-to-head data comparing its JAK inhibitor Xeljanz to Humira would help steal market share, but the newer drug showed mixed results.
By Suzanne Elvidge • June 19, 2017 -
EpiPen alternative Symjepi gets FDA OK
Adamis Pharmaceuticals plans to launch its allergic reaction drug later this year.
By Jacob Bell • June 16, 2017 -
Pfizer, Roche, Aspen under investigation for cancer drug pricing
South African's Competition Commission is looking into the "excessive pricing" of Herceptin, Xalkori and a few generic medications.
By Jacob Bell • June 14, 2017 -
Rebates not to blame for rising drug costs, says PBM trade group
A new report from PCMA found no correlation between rebate levels and increasing prescription drug costs among the top 200 brands.
By Ned Pagliarulo • June 14, 2017 -
Report: Pharma spend helps push medical costs up
New research from PwC expects inflation, a lack of generic drugs and a more tepid response to high-deductible insurance plans are likely to increase medical costs next year.
By Jacob Bell • June 14, 2017 -
Sponsored by ZS AssociatesHow biopharma companies can adapt to industry changes
Commercial organizations in the biopharma industry need to move away from generalist roles into more specialized roles.
By Jude Konzelmann and Karan Dhundia • June 13, 2017 -
Deep Dive
Alternative pricing models a fantasy for gene therapies?
With an approval of Spark Therapeutics' gene therapy for a rare eye disease rapidly approaching, new questions about pricing are being raised.
By Lisa LaMotta • June 12, 2017
Previous
